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Abstract 
Introduction: It is not known if inhaled antibiotics improve respiratory symptoms in patients with 
bronchiectasis. In the recent phase-3 ORBIT trials, 48-weeks treatment with ARD-3150 (inhaled 
liposomal ciprofloxacin) did not significantly improve symptoms using the prespecified method of 
analysis comparing baseline symptoms to those after 48 weeks, when patients had been off treatment 
for 28 days. This method of analysis does not take account of possible improvements in symptoms while 
on active treatment. 
Methods: A post-hoc analysis of 2 identical randomized trials of ARD-3150 (ORBIT-3 and -4) 
administered 28-days on and 28 days off in patients with bronchiectasis and chronic Pseudomonas 
aeruginosa infection. The quality of life bronchiectasis respiratory symptom scale (QOL-B-RSS), which 
has a 1-week recall period, was administered every 28-days. We examined whether respiratory 
symptoms improved during on-treatment periods and the relationship of changes in QOL-B-RSS to 
changes in bacterial load using a mixed model repeated measures approach. 
Results: ARD-3150 treatment resulted in a significant improvement in respiratory symptoms during the 
on-treatment periods with concordant results between ORBIT-3 (estimate 1.4 points, standard error (SE) 
0.49,p=0.004) and ORBIT-4 (estimate 1.1 point, SE0.41,p=0.006). The proportion of patients achieving a 
symptom improvement above the minimum clinically important difference was higher with ARD-3150 
compared to placebo during on-treatment cycles (p=0.024). Changes in respiratory symptoms were 
correlated with changes in bacterial load in the treatment group (r=-0.89,p<0.0001). Individual estimates 
for decrements in the QOL-B RSS during exacerbation were -9.4 points (SE 0.91) in ORBIT-3 and -10.8 
points (0.74) in ORBIT-4 (both p<0.0001).  
Conclusion: Inhaled ARD-3150 resulted in significant improvements in respiratory symptoms during the 
on-treatment periods which were lost during off-treatment periods. These results supports the concept 








The symptoms of bronchiectasis include daily cough, sputum production, breathlessness, chest pain and 
fatigue.(1) These symptoms combined with the impact of frequent exacerbations result in impairment of 
quality of life.(2) Symptoms and quality of life are most severely impaired in patients with chronic 
Pseudomonas aeruginosa infection.(3,4) Patients with chronic P. aeruginosa infection had a 7.5 points 
higher score on the St Georges Respiratory Questionnaire (SGRQ) in an analysis of European Registry 
data, even after adjustment for underlying severity of disease.(4) In a survey of more than 1000 patients 
with bronchiectasis, sputum production was rated as the most severe symptom, followed by 
exacerbations, fatigue, shortness of breath and cough.(5) Finding treatments that could reduce these 
symptoms as well as the frequency of exacerbations was rated as the key research priority.(5) 
There are currently no approved treatments to improve symptoms in bronchiectasis. Patients are 
advised to perform airway clearance, which can improve symptoms and quality of life.(6) Macrolides 
have been shown to reduce exacerbations but have not demonstrated a clinically meaningful effect on 
symptoms.(7) In bronchiectasis patients with chronic airway infection there is evidence that the 
symptom burden is correlated with the airway bacterial load.(8,9) Higher airway bacterial counts 
promote neutrophil recruitment and release of inflammatory mediators that directly stimulate mucus 
production, plugging, bronchoconstriction and increase sputum volume and viscosity through release of 
inflammatory cell DNA.(10,11) Thus effective antibiotic therapy would be expected to improve 
symptoms in bronchiectasis by decreasing airway bacterial load that leads to reduced inflammation.  
Inhaled antibiotics are highly effective in reducing bacterial load in the respiratory tract but to date 
there is no consistent evidence that they can improve symptoms.(12) In a recent meta-analysis of 16 
trials and 2597 patients, bacterial load was consistently reduced by all antibiotics tested, but there was 
no statistically significant improvement in the quality of life bronchiectasis questionnaire respiratory 
symptom score (QOL-B RSS)  when the data were pooled.(12) Thus the meta-analysis concluded that 
inhaled antibiotics reduce exacerbations but have no effect on quality of life or symptoms.(12) 
This conclusion may be confounded by the method of analysis used. Most studies were conducted using 
a 28-day on and 28-day off cyclical regimen designed to limit antibiotic resistance, by allowing antibiotic 
susceptible bacteria to recover during the off-periods.(13,14) Most studies, including the ORBIT-3 and -4 
trials of ARD-3150 (inhaled liposomal ciprofloxacin), evaluated symptoms at the end of the last off 
treatment period.(15) As the QOL-B RSS has a recall period of only one week this method of analysis 
ignores changes in symptoms during the course of the study while on treatment and may therefore 
underestimate the effect of inhaled antibiotics on symptoms. 
We hypothesised that improvements in symptoms during the ORBIT-3 and -4 studies of ARD-3150 would 
occur during “on-periods” when bacterial load is suppressed and that analysis of symptoms continuously 






The ORBIT-3 and -4 studies 
A detailed description of the methodology of the ORBIT trials was previously published.(15) In brief 
these were 2 replicate phase 3 randomized double-blind placebo controlled trials conducted between 
March 31 2014 and August 19 2015. Both studies enrolled patients from 16 countries worldwide. The 
inclusion criteria were adult patients aged 18 year or older with a clinical diagnosis of non-cystic fibrosis 
bronchiectasis confirmed by chest computed tomography (the protocol used the term non-cystic fibrosis 
bronchiectasis, for simplicity we use the term bronchiectasis throughout the rest of the manuscript). 
Patients had a history of at least 2 pulmonary exacerbations treated with antibiotics in the previous year 
and an FEV1 of greater than or equal to 25% predicted.(15) Patients had chronic P. aeruginosa infection 
as documented on respiratory samples prior to the screening visit and were required to have at least 
one non-resistant P. aeruginosa isolate on a sputum sample taken at screening. Exclusion criteria 
included a pulmonary exacerbation during the 28-days prior to randomization, a primary diagnosis of 
chronic obstructive pulmonary disease related to cigarette smoking of at least 10 pack years, cystic 
fibrosis and active allergic bronchopulmonary aspergillosis or mycobacterial infection requiring 
treatment. Oral or inhaled antipseudomonal antibiotics were also not permitted. For full inclusion and 
exclusion criteria readers are referred to the primary trial publication.(15)  
Patients were randomized 2:1 to receive either ARD-3150 or placebo (dilute liposomes in isotonic saline) 
for 48 weeks administered 28-days on and 28 days off. Randomization was stratified by sex, smoking 
status and number of pulmonary exacerbations in the 12 months prior to randomization. The primary 
outcome was time to first exacerbation with key secondary outcomes of frequency of exacerbations and 
change from baseline to 48 weeks in the QOL-B RSS.(15)  
Post-hoc analysis of the quality of life respiratory symptom score 
The QOL-B questionnaire is a 32 item patient reported outcome measure developed for use in 
bronchiectasis trials.(16) The respiratory symptom domain has been extensively used to measure 
respiratory symptoms in bronchiectasis and has been shown to correlate with other measures of health 
status as well as being responsive to change in the context of exacerbations.(9,13,14,16,17) The 
questionnaire has a 7-day recall period. The QOL-B RSS was administered at the end of each on-
treatment and off-treatment period. In individuals who were experiencing a protocol defined 
exacerbation at the time of a scheduled visit this was recorded, allowing assessment of the changes in 
symptoms associated with an exacerbation. The pre-specified secondary endpoint in the trials was the 
difference between the baseline QOL-B RSS score and the score measured at the end of the final off-
treatment cycle.(15) 
In a post-hoc analysis we modelled these repeated measurements of the QOL-B RSS to evaluate the 
impact of treatment on changes in symptoms during on-treatment cycles. Co-variates likely to impact on 
changes in symptoms were also evaluated including stable baseline macrolide use, occurrence of a 
pulmonary exacerbation, use of antibiotics for a respiratory cause that did not meet the criteria for a 
protocol defined exacerbation, sex, smoking and baseline exacerbation frequency. We also evaluated 
the relationship between P. aeruginosa colony forming units per ml (cfu/ml) in sputum and changes in 
QOL-B RSS.  
 
Statistical analysis 
We developed two statistical models to investigate the relationship between the on/off treatment with 
ARD-3150 and presence of respiratory symptoms.   
 
The first approach to estimate absolute changes in symptoms comparing ARD-3150 to placebo was a 
mixed model repeated measures (MMRM) model.  Absolute QOL-B change from baseline was the 
dependent variable for the model and independent variables were as follows: treatment period, ARD-
3150 treatment during an on-cycle, stable macrolide use at baseline, use of antipseudomonal antibiotics 
for a non-protocol defined exacerbation, presence of a protocol defined exacerbation during the time 
the questionnaire was administered, all two-way interactions of the above variables and the three 
stratification variables. A global test was performed to assess all two-way interactions in the model, with 
the exception of the treatment-period interaction. If this test was not statistically significant, the 
specified two-way interactions were eliminated from the model.  If non-significant, two additional 
model tests were made:  first it was determined if a "saw tooth" shape was present in the ARD-3150 and 
placebo independently, and then whether the minimum of the ARD-3150 saw tooth was not different 
from the minimum of the placebo "saw tooth" (or placebo regression line if no placebo "saw tooth" was 
observed). 
 
The second statistical approach was designed to determine whether the proportion of patients 
experiencing a clinically significant improvement in symptoms was greater with ARD-3150 compared to 
placebo. We used a generalized estimating equations (GEE) model with a binary dependent variable 
indicating if the QOL-B absolute response was more than 8 points higher than the subject's baseline 
QOL-B value and the following independent covariates: treatment period, ARD-3150 treatment during 
an on-cycle, stable baseline macrolide treatment, occurrence of a pulmonary exacerbation during the 
time that the questionnaire was administered and antibiotic treatment for a non-protocol defined 
exacerbation.  The Minimum Clinically Important Difference (MCID) for the QOL-B is considered to be 
greater than 8 points(16).  The odds that a patient would have an improvement above the MCID 
(greater than or equal to 8.5 points) at each study visit was modelled in GEE using a logistic-link 
function. The same stepwise progression for model development described in the MMRM model was 
again used in the GEE model. 
 
The relationships between mean quality of life changes stratified by sex, stable macrolide use at baseline and 
prior number of exacerbations, and mean change in P. aeruginosa load expressed as CFU/g were calculated 
using the Spearman rank correlation statistic.  
 
In all analyses, statistical significance was inferred at a p-value less than 0.05. Analyses are considered 
exploratory in view of their post-hoc nature.  
Results 
In ORBIT-3 183 patients were randomized to ARD-3150 and 95 patients to placebo. In ORBIT-4 206 
patients were randomized to ARD-3150 and 98 patients to placebo. As previously reported there were 
no significant baseline imbalances in the groups in terms of age, sex, FEV1 or baseline exacerbation 
history, but there was an imbalance in baseline macrolide use (23% vs 14% in ORBIT-3 comparing active 
vs placebo respectively and 17% vs 24% in ORBIT-4). The mean QOL-B RSS scores at baseline were 54.2 
for ARD3150 and 53.6 for placebo in ORBIT-3 with the equivalent scores being 57.7 and 56.9 in ORBIT-4.  
In the original pre-specified analysis, ARD-3150 did not result in improved respiratory symptoms. 
Change in QOL-B score from baseline to week 48 was -1.62 (95% CI -5.66, 2.34,p=0.43) and -0.08 (95% CI 
-2.86, 2.70,p=0.95) respectively in ORBIT-3 and -4. 
Figure 1 shows the mean QOL-B RSS scores in ORBIT-3 and -4 over the course of the study. Marked 
improvements in the QOL-B scores were observed over the first 28 days in both the active and placebo 
group with separation between groups subsequently appearing in both studies. The mean change from 
baseline was 3.7 and 4.0 points for the ARD3150 and placebo groups in ORBIT-3 and 7.85 and 4.4 points 
respectively in ORBIT-4.    
The final MMRM model stepped down to a model containing the treatment-period interaction, the 
placebo response curve having no "saw tooth" shape and being equivalent to the intercept value, and 
the ARD-3150 treated group having a "saw tooth" shape with a minimum equal to the intercept.  Other 
significant independent variables were: stable baseline macrolide treatment, occurrence of a pulmonary 
exacerbation during the time that the questionnaire was administered and antibiotic treatment for a 
non-protocol defined exacerbation.  
The changes in symptoms within the active treatment arm can be seen to follow a saw tooth pattern 
with improvements at the end of each on-treatment period (day 28, 84, 140, 196, 252, 308) and declines 
at the end of all but one of the off periods (the 5th off treatment period in ORBIT-4). We therefore 
explored whether changes in the QOL-B scores followed changes in P. aeruginosa load. 
In the ARD-3150 treatment group there was an association between change in QOL-B RSS and the 
change in cfu/g which was not evident in the placebo group. The QOL-B score improved during the on 
treatment periods and declined during off-treatment periods in parallel with decreases and increases in 
the P. aeruginosa load. The correlation between change in CFU and change in QOL values was -0.89 95% 
CI -0.76-0.95,p<0.0001 for the pooled data, -0.92 95% CI 0.71-0.98,p<0.0001 for ORBIT-3 and -0.89 95% 
CI 0.65-0.97,p=0.0002 for ORBIT-4. The corresponding correlation in the placebo group were 0.05,p=0.8 
for the pooled data. 
 
Analysis of repeated measures of respiratory symptoms using the QOL-B RSS 
Analysis of repeated measures found a statistically significant effect of treatment with ARD-3150 on 
QOL-B RSS score at the visits at the end of the on-treatment periods. The results of the model for the 
pooled ORBIT-3 and -4 studies are shown in table 1. Significant effects on QOL-B RSS were observed for 
ARD-3150 treatment, protocol defined exacerbations and use of antipseudomonal antibiotics that did 
not meet the criteria for a protocol defined exacerbation. Stable macrolide use at baseline was also 
associated with worse symptoms.  
Results were concordant between ORBIT-3 where the estimated effect of treatment was an 
improvement of 1.4 points (standard error- SE 0.49), p=0.004 and ORBIT-4 where the estimate was an 
improvement of 1.1 points (SE 0.41),p=0.006.  
Individual estimates for decrements in the QOL-B RSS during an exacerbation were -9.4 points (SE 0.91) 
in ORBIT-3 and -10.8 points (0.74) in ORBIT-4 (both p<0.0001).  
 




On-treatment cycle for ARD3150 1.29 0.32 < 0.001 
Protocol defined PEn at time of questionnaire -10.16 0.57 < 0.001 
Anti-Pseudomonal antibiotic use for respiratory event 
not meeting the criteria for a PE 
-4.15 0.73 < 0.001 
Macrolide treatment at baseline (yes vs no) -4.53 1.71 0.009 
Sex (M vs F) 2.39 1.47 0.10 
PE category in the previous year (4+ vs 2-3) -2.44 1.68 0.15 
Smoking Stratum (smoker vs non-smoker) -0.04 7.32 1.00 
Table 1. Mixed model for repeated measures for the pooled ORBIT-3 and -4 studies. Abbreviations (PE= 
pulmonary exacerbation, M=male, F=female) 
 
Controlling for the absence during the trial of: a pulmonary exacerbation; any treatment with 
macrolides; and the absence of treatment with anti-pseudomonal antibiotics for a non-protocol defined 
eexacerbation, this model reduced to a flat response curve for subjects treated with placebo and as a 
sawtooth shaped curve for subjects treated with ARD-3150. The minimum of the modelled sawtooth 
touched the placebo response line just before the beginning of the active cycle and the maximum of the 
modelled sawtooth was 1.0 to 1.5 units higher than the minimum. (Figure 3).  
 
Analysis of clinically significant improvement in symptoms 
The GEE model using the binary MCID variable (improvement greater than or equal to 8.5 points as a 
clinically important improvement in symptoms) was used to describe clinically significant changes in the 
QOL-B RSS.(16) The final shape of the response curve had an analogous treatment-period shape to the 
model described in the MMRM model. In the GEE for the pooled ORBIT-3 and -4 studies, ARD-3150 on 
treatment cycles were associated with a statistically significant increase in the probability of 
experiencing a clinically meaningful improvement in QOL-B RSS (estimate -0.11 95% CI -0.02 to -
0.21,p=0.024). The presence of a protocol defined pulmonary exacerbations and antibiotic use for 
respiratory events not meeting the criteria for a pulmonary exacerbation were also associated with 
statistically significant worsening of symptoms above the MCID (p<0.001 for both). This again shows that 
at the end of on-treatment cycles there was a small but significant increase in patients reporting 
clinically significant improvements in symptoms. Full model results are displayed in table S1 online.  
Since we observed an improvement in respiratory symptoms, we investigated the extent to which this 
could be balanced by a worsening in the treatment burden domain of the QOL-B due to treatment 
exposure. Changes in the treatment burden domain are shown in figure S1 online. This showed in both 
ORBIT 3 and 4 an increase in treatment burden from baseline to the first on-treatment visit that then 
remained relatively stable throughout the study.  
 
Discussion 
Forty eight weeks treatment with inhaled ARD-3150 resulted in clinically and statistically significant 
improvements in respiratory symptoms assessed using the QOL-B RSS compared to placebo when taking 
into account the dynamic changes in symptoms that occur over time and particularly the effects of 
treatment during the on-treatment periods. Importantly, although the average change in the symptom 
score was less than the MICD, a significantly greater proportion of patients experienced clinically 
significant improvements in symptoms with ARD-3150 compared to placebo. The original conclusions of 
the ORBIT-3 and -4 studies were that there was no significant effect of treatment.(15) This reflects the 
pre-specified secondary endpoints which was the difference between the baseline and the end of trial 
values for the QOL-B RSS. As can be seen in figure 1, the difference at the single point in time at the end 
of the trial when patients had been off treatment for 28 days did not reflect the variable symptoms 
experienced by patients during the full 48 weeks. Bronchiectasis is a long term condition and therefore 
in retrospect evaluating symptoms at a single point in time while off treatment, using a tool with a 7-day 
recall period, clearly did not accurately reflect long term variation in symptoms.  
A recent meta-analysis concluded that inhaled antibiotics do not significantly improve respiratory 
symptoms.(12) This is reflected in international guidelines for bronchiectasis where inhaled antibiotics 
are recommended to prevent exacerbations in patients with P. aeruginosa and at least 3 exacerbations 
per year and are not recommended for treatment of symptoms.(18) Our analysis, however, 
demonstrates that inhaled antibiotics can be shown to improve respiratory symptoms if appropriate 
methods of analysis are employed. There are likely to be patients where such treatment may be 
indicated to improve symptoms in addition to reducing exacerbations. This is consistent with some 
individual studies where symptom benefits have been observed.(19) 
The key conclusions of this study are firstly, that evaluation of symptoms in bronchiectasis trials should 
consider the use of MMRM to demonstrate the dynamics of symptom changes over time. This increases 
statistical power to demonstrate effects and is more reflective of the reality of a long term chronic 
condition. Secondly, there is a clear relationship between reductions in bacterial load and changes in 
respiratory symptoms in the ORBIT-3 and -4 studies in patients receiving ARD-3150. This adds to the 
emerging evidence that bacterial load measured as colony forming units per gram in sputum is a key 
biomarker in bronchiectasis.(8,9,20) Patients with higher bacterial loads have higher levels of airway 
inflammation measured through neutrophil elastase activity and cytokines/chemokines such as IL-1β 
and CXCL8.(9,20,21) Higher bacterial load predicts a higher frequency of exacerbations and hospital 
admissions during follow-up and most importantly a recent re-analysis of the AIR-BX trials of inhaled 
aztreonam suggested that bacterial load predicted response to inhaled antibiotics in terms of 
respiratory symptoms.(8,9) Limitations of the study by Sibila et al include that the AIR-BX studies 
enrolled patients with a mixture of different pathogens and patients without baseline pathogens, and 
that follow-up in the study was limited to just two cycles of antibiotics.(9,17) The present analysis of the 
ORBIT-3 and -4 studies therefore provides more robust evidence of the relationship between CFU 
reductions and symptomatic improvements by demonstrating a correlation between these two variables 
across 6 cycles over 48 weeks in 2 replicate trials. The consistency of this signal across multiple inhaled 
antibiotic studies strengthens the value of bacterial load as a surrogate endpoint and “treatable 
trait”.(22,23)  
A third key conclusion of this work is that the intermittent administration of antibiotics using 28-day on 
and 28-day off regimens results in improvements in symptoms during the on-period but a relapse in 
symptoms during the off-period when bacterial loads increase back to baseline levels. This phenomenon 
is well recognised in cystic fibrosis where many patients have taken to administering a second antibiotic 
during the “off periods” to avoid this rebound in bacterial load and consequent worsening of health 
status.(24) There has been an active debate for many years over whether continuous or intermittent 
administration of inhaled antibiotics is the optimal approach.(25) The intermittent approach using 28 
day or 14 day cycles has been used because of a belief that removing antibiotic selection pressure for a 
period would allow regrowth of the antibiotic sensitive bacterial flora and therefore limit the emergence 
of resistance.(13,14) There are no head to head studies of intermittent vs continuous antibiotic 
administration.(25) Our results nevertheless suggest that continuous administration of ARD-3150 and 
perhaps other inhaled antibiotics may be more beneficial in terms of maintaining symptom 
improvements because continuous bacterial suppression appears to be required to continuously lower 
symptom burden. Such an approach would need to be weighed against the theoretical risk of greater 
resistance emergence and the increased cost and treatment burden. It is recognised that the QOL-B RSS 
measures symptoms in isolation and that quality of life is also influenced by other factors including 
potentially being negatively impacted by the need to take regular treatment.  
It should be noted that the differences we observed in the ORBIT-3 and -4 studies between ARD-3150 
and placebo were small, with average differences between active and placebo groups of only 1-2 points 
in the QOL-B RSS, a level below the MICD.(16) Only a proportion of patients would therefore be likely to 
gain a clinically meaningful change in symptoms. Nevertheless, the MCID for QOL-B is not well 
established and individual patients should be allowed to decide if their changes in symptoms are 
clinically meaningful. One reason that this difference was small is the large placebo effect we observed. 
As illustrated in figure 1, randomization to placebo was associated with a mean 4.4 and 4.0 point 
improvement in the QOL-B RSS between baseline and day 28, an effect which never returned to baseline 
during the trial. Further research is needed to understand placebo effects in the context of 
bronchiectasis randomized trials. Several large studies have now observed large placebo effects in terms 
of quality of life improvements or reductions in exacerbation frequency from a past history of more than 
2 exacerbations to mean exacerbation frequencies of less than 1 during a 1 year observation 
period.(13,14,26,27) It is well documented that patients may change their behaviour during a trial, 
becoming more adherent to other therapies or changing their lifestyles in a way that promotes 
improved health status. Other explanations for the observed behaviour are possible.  
Our study also demonstrates the important impact that pulmonary exacerbations have on patients 
quality of life. Pulmonary exacerbations meeting the protocol definition were associated with a 
decrement in symptoms of approximately 10 points. Previous work suggests that the symptoms of 
exacerbations last for several weeks and that approximately 20% of patients do not return to their usual 
health status by 1 month post event.(28) The changes observed in this study were somewhat lower than 
the 14-point decrement observed in 60 patients in the AIR-BX studies used to validate the QOL-B. The 
difference may be due to the much larger sample size in our study or differences in the study 
population.(16) Our post-hoc analyses show that the treatment with ARD-3150 improves QOL-B RSS 
independent of occurrence of PEs as well as by reducing the number of these events. 
The lessons learnt from ORBIT-3 and -4 will inform the next generation of clinical trials in bronchiectasis. 
However, this study also important limitations. The analyses are posthoc and hence the findings should 
be considered exploratory and p-values interpreted with caution. The QOL-B RSS was the only health 
status measure included in the ORBIT-3 and -4 studies. Other studies such as the RESPIRE trials 
documented different results between the QOL-B which has a 1 week recall period and the St Georges 
Respiratory Questionnaire which has a longer recall period and different questions.(13,14) Future 
studies are required to identify the optimal symptom tool in bronchiectasis. Our study was not designed 
to look at the question of which individual patients had the best overall symptom response as this is a 
separate research question and should be addressed in future research. 
In summary, ARD-3150 resulted in a small but significant improvement in respiratory symptoms over 48 
weeks. Future randomized trials should use the repeated measures approach used in this study to 
account for changes across the full duration of the trial. Symptoms change in line with changes in 
bacterial load during on-treatment periods confirming bacterial load as a key biomarker of inhaled 
antibiotic response in bronchiectasis.  
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Figure 1. Mean QOL-B RSS scores in the active and placebo groups during the ORBIT-3 and ORBIT-4 
studies.  
 
Figure 2. Relationship between changes in cfu/g and QOL-B RSS in the active treatment and placebo 
group. A positive change in QOL-B RSS represents an improvement.  
 
Figure 3. Results of the mixed model repeated measures for the pooled ORBIT 3 and 4 studies. The 
maximum has been allowed to vary according to the observed mean at each treatment cycle for the 
ARD-3150-treated group, and the placebo response rate has been set to the grand mean for the 
placebo-treated subjects. 
 
Figure 4. Results of the GEE model for the pooled ORBIT 3 and 4 studies. The maximum has been 
allowed to vary according to the observed mean at each treatment cycle for the ARD-3150-treated 
group, and the placebo response rate has been set to the average response rate for the placebo-treated 
subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
